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Abstract  Catheter-based  renal  denervation  is  a  new  method  able  to  disrupt  renal  sympa-
thetic nerves  located  in  the  adventitia  of  renal  arteries.  A  randomized  clinical  trial  showed
a decrease  in  blood  pressure  in  resistant  hypertensive  patients.  In  order  to  guide  clinicians
and interventional  practitioner  for  the  use  of  this  new  approach,  different  French  scientiﬁc
societies (Hypertension,  Cardiology  and  Radiology)  decided  to  combine  their  expertise  and  pro-
pose an  expert  consensus  to  assess  beneﬁt/risk  ratio  of  this  technique  in  the  ﬁeld  of  arterial
hypertension.  In  2012,  this  expert  consensus  propose  to  limit  renal  denervation  technique  to
patients with  essential  hypertension  uncontrolled  by  four  or  more  antihypertensive  therapies
with at  least  one  treatment  being  a  diuretic  and  spironolactone  at  a  dose  of  25  mg  shown  to  be
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unable  to  control  blood  pressure.  Measurement  of  ofﬁce  BP  should  be  at  least  with  SBP  more
than 160  mmHg  and/or  DBP  more  than  100  mmHg  conﬁrmed  by  ambulatory  BP  measurement
(home or  ABP  measurement  with  SBP  more  than  135  mmHg  and  DBP  more  than  85  mm  during
daytime period).  Finally,  renal  artery  anatomy  and  function  should  allow  proper  intervention
(i.e., two  functional  kidneys,  absence  of  previous  renal  angioplasty).  Renal  enervation  is  a
complex interventional  procedure  with  potentially  arterial  complications,  training  is  required
for practitioners.  Antihypertensive  treatment  should  not  be  interrupted  immediately  after  renal
denervation  since  blood  pressure  lowering  effect  are  delayed  and  reached  maximum  effect
after 3  months.  Monitoring  of  blood  pressure,  renal  function  and  anatomy  of  renal  arteries  is
required 12  months  and  36  months  after  procedure.  The  expert  consensus  requires  the  inclusion
of patients  experiencing  this  procedure  in  a  observational  study  with  record  form  and  follow-up.
© 2012  Éditions  françaises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
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•Renal  denervation  via  the  endovascular  route  is  a  new
method  for  which  a  randomised  clinical  study  showed  a
decrease  in  blood  pressure  (BP)  in  patients  with  hyperten-
sion  (HT)  who  were  resistant  to  antihypertensive  agents.  A
speciﬁc  device  (catheter  and  generator)  that  allow  for  renal
denervation  has  been  commercially  available  in  France  since
2011.  It  makes  it  possible  to  perform  renal  denervation  using
a  low-energy  radiofrequency  current,  the  thermal  effect  of
which  will  reach  by  dissipation  the  adventitia  of  the  renal
artery  in  which  the  sympathetic  nerve  ﬁbres  are  located  that
will  then  be  destroyed.
The  rules  of  good  use  of  this  medical  device  have  yet
to  be  published  in  the  recommendations  of  knowledgeable
societies.  Several  knowledgeable  French  societies  bringing
together  specialists  in  HT,  cardiology  and  interventional
radiology  have  wanted  to  provide  guideposts  and  rules  of
good  uses  for  clinical  and  interventional  physicians  concern-
ing  the  indications,  the  procedure  and  the  follow-up  of  renal
denervation  for  the  treatment  of  HT.
This  document,  which  was  written  by  expert  consensus,
may  be  adapted  depending  on  changes  in  new  devices  made
available  to  medical  professionals,  but  also  clinical  studies,
the  results  of  which  will  become  known  in  the  months  and
years  to  come.
Resistant hypertension: current diagnosis
and treatment
HT  is  the  most  common  CV  risk  factor  and  chronic  disease
in  France,  with  more  than  12  million  patients  treated  with
antihypertensive  agents.  Despite  the  means  implemented  to
treat  HT,  the  control  of  HT  in  treated  hypertensive  patients
remains  insufﬁcient,  as  HT  control  deﬁned  as  BP  less  than
140  and  90  mmHg  in  consultation  is  only  achieved  in  50%  of
treated  patients  [1].  When  a  treated  hypertensive  patient
does  not  reach  the  BP  objective,  he  or  she  is  described
as  having  uncontrolled  HT.  In  this  situation,  the  treatment
should  include:
• an  evaluation  of  the  correct  compliance  with  the  pre-
scribed  treatments;
• a  reinforcement  of  advice  and  non-medicinal  monitor-
ing  measures  with  restriction  of  sodium  chloride  intake
via  a  reduction  in  the  amount  of  foods  that  are  rich
in  ‘‘hidden  salt’’  (bread,  cheese,  preserved  meats),
t
pfollow-up  of  nutritional  measures  that  make  it  possible
to  lose  4  to  5  kg,  a  decrease  in  consumption  of  alcoholic
beverages;
a  rationalisation  of  the  use  of  antihypertensive  agents
with  the  optimisation  of  the  choice  of  pharmacological
groups.  If  the  efﬁcacy  of  monotherapy  is  insufﬁcient,
bitherapy  should  be  initiated,  followed  by  tritherapy,
which  should  include:  a  renin-angiotensin  system  blocker
(ARA2  or  ACE  inhibitor  or  direct  renin  inhibitor),  a
calcium-channel  blocker  and  a thiazide  diuretic.
When  a  treated  hypertensive  patient  has  not  reached  the
P  objective  despite  the  prescription  of  tritherapy  including
edicinal  products  prescribed  at  the  maximum  tolerated
osage  and  including  a  diuretic,  he  or  she  is  described  as
aving  ‘‘resistant  HT’’,  according  to  the  deﬁnition  used  in
he  recommendations  [2].  In  order  to  conﬁrm  the  diagnostic
f  resistant  HT,  treatment  should  include:
an  ambulatory  measurement  of  BP  (AMBP)  or  automatic  BP
measurement  (ABPM)  in  order  to  check  the  permanence
of  the  lack  of  BP  control,  with  a  BP  decision  threshold  of
135  and/or  85  mmHg  for  the  daytime  mean  of  AMBP  or  the
mean  ABPM;
laboratory  and/or  radiology  tests  in  order  to  screen  for
secondary  HT  [2].  The  most  common  causes  of  secondary
HT  are  as  follows:  nephropathy,  sleep  apnoea,  adrenal
causes  and  renal  artery  stenosis.
Resistant  HT,  when  conﬁrmed,  requires  specialised  treat-
ent  as  per  the  recommendations  [2].  Treatment  should
nclude:
reinforcement  of  treatment  (increase  of  the  dose  of  anti-
hypertensive  agents  up  to  the  maximum  tolerated  dose,
choice  of  another  diuretic);
the  addition  of  an  aldosterone  antagonist  (spironolac-
tone);
the  addition  of  other  pharmacological  groups  (alpha
blockers,  central  antihypertensive  agents,  direct
vasodilatory  agents);
use  of  ﬁxed  combinations  of  antihypertensive  agents;
use  of  AMBP  to  monitor  the  efﬁcacy  of  the  treatments;
normalisation  of  salt  intake.The  incidence  of  resistant  HT  in  populations  of  hyper-
ensive  patients  is  very  variable  and  depends  on  several
arameters:  studied  population,  etiological  assessment,
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resence  of  severe  renal  insufﬁciency,  specialized  treat-
ent.  The  data  obtained  or  a  general  population  living
n  the  USA  between  2003  and  2008  indicate  that  resistant
T  is  observed  in  approximately  9%  of  treated  HT  patients
3].  Patients  with  resistant  HT  are  exposed  in  a  premature
anner  to  target  organ  damage  and  to  the  early  onset  of
ardiovascular  (CV)  complications  leading  to  an  increase
n  morbidity  and  mortality.  It  has  been  shown  that  the  CV
rognosis  is  directly  related  to  the  BP  level,  which  justiﬁes
he  treatment  of  resistant  HT  in  order  to  obtain  BP  control
4].  When  resistant  HT  is  not  controlled  despite  specialized
reatment,  an  improvement  in  BP  control  has  recently  been
ade  possible  through  the  use  of  interventional  techniques
hat  act  on  the  nervous  regulation  of  BP.  Vagal  stimulation
ia  baroreﬂex  activation  and  renal  denervation  by  catheter-
zation  of  the  renal  arteries  are  two  methods  that  have
ecently  been  developed  [5,6]. Their  use  in  the  treatment
f  resistant  HT  is  not  explicit  in  the  recommendations.  The
bjective  of  the  creation  of  an  expert  consensus  on  the  use
f  renal  denervation  in  HT  is  to  deﬁne  the  indications  of
he  method,  to  help  perform  the  technique  properly  and  to
rganize  patient  follow-up.
hysiopathological mechanisms and
rerequisites for the use of renal
enervation in hypertension
ole of the autonomic nervous system in the
hysiopathology of hypertension
he  autonomic  nervous  system  participates  in  the  phys-
opathology  of  HT  via  an  activation  of  the  sympathetic
ystem,  the  central  or  peripheral  origin  of  which  depends
n  reﬂexes  (baro,  chemical  or  mechanical  reﬂexes)  or
umoral  substances  [7].  The  involvement  of  the  renal  sym-
athetic  nervous  system  in  the  regulation  of  BP  is  complex,
ue  to  the  role  played  by  the  efferent  sympathetic  tone
estined  for  the  renal  parenchyma  and  by  the  afferent
ympathetic  tone  from  the  kidneys.  Therefore,  the  renal
ympathetic  system,  which  participates  in  the  regulation
f  BP,  plays  a  role  in  the  initiation  and  persistence  of
T.
ole of the renal sympathetic nervous system
n blood pressure
n  the  kidneys,  efferent  sympathetic  innervation  is  destined
or  the  vascular  system,  renal  tubules  and  juxtaglomerular
pparatus.  Stimulation  of  the  sympathetic  system  partic-
pates  in  vascular  constriction  via  two  mechanisms:  the
timulation  of  the  beta-adrenergic  receptors  of  the  jux-
aglomerular  apparatus  leading  to  the  stimulation  of  the
enin-angiotensin  system  and  the  increase  in  volaemia;  and
he  stimulation  of  vascular  alpha-adrenergic  receptors  lead-
ng  to  direct  vascular  constriction.  The  reduction  in  efferent
enal  sympathetic  tone  activity  via  experimental  methods
f  renal  denervation  has  reduced  BP  in  different  animal
odels  [8].  Renal  sympathetic  afferences  participate  in  the
odulation  of  the  activity  of  the  central  sympathetic  sys-
em.  They  become  involved  via  stimuli  detected  by  the
w
•A.  Pathak  et  al.
echanical  and  chemical  receptors  located  in  the  kidneys
hat  are  sensitive  to  variations  in  electrolyte  concen-
rations,  plasma  osmolality  and  hypoxia  caused  by  renal
schaemia  [9].  The  interruption  of  renal  sympathetic  affer-
nces  obtained  via  nephrectomy  is  accompanied  by  a
eduction  in  the  total  sympathetic  activity  and  a  decrease
n  BP  [10]. Renal  denervation  by  a  surgical  method  is  accom-
anied  by  a  reduction  in  peripheral  and  central  sympathetic
ctivity  and  a  reduction  in  the  release  of  renin  without  a
hange  in  the  glomerular  ﬁltration  rate.  The  surgical  dener-
ation  techniques  (splanchnectomy,  sympathectomy)  are  no
onger  used,  as  serious  complications  (orthostatic  hypoten-
ion,  impotence,  sphincter  incontinence)  were  observed
fter  these  procedures  [11].
rinciples of renal denervation by
adiofrequency applied via the endovascular
oute
enal  denervation  via  radiofrequency  applied  via  the
ndovascular  route  is  a  method  that  destroys  peripheral
erve  ﬁbres  the  surround  the  trunk  of  the  renal  arteries  [6].
t  causes  a  reduction  in  sympathetic  tone  of  renal  origin  with
 decrease  in  BP.
linical studies on renal denervation by
adiofrequency in the treatment of
ypertension
he SIMPLICITY 1 and 2 studies: inclusion of
ubjects with resistant hypertension without
enal insufﬁciency with compatible renal
rterial anatomy
wo  clinical  studies  evaluated  the  effects  of  renal  den-
rvation  via  radiofrequency  in  patients  with  resistant  HT
12,13].  SIMPLICITY  1  (n  =  50)  is  the  pilot  feasibility  study
13],  and  SIMPLICITY  2  (n  =  106  randomised  patients  for  190
re-selected  patients)  [12]  is  the  randomized  study  carried
ut  in  patients  with  resistant  HT  evaluating  the  efﬁcacy  of
enal  denervation  on  BP  compared  to  a  group  treated  with
edicinal  products.  The  inclusion  criteria  were  very  close  in
oth  protocols.  The  included  patients  corresponded  to  the
eﬁnitions  of  treated  and  uncontrolled  HT:
systolic  BP  in  consultation  (mean  of  three  measurements)
greater  than  160  mmHg  or  greater  than  150  mmHg  in
patients  with  diabetes;
treatment  with  at  least  three  antihypertensive  agents
that  should  include  a  diuretic  (SIMPLICITY  1);
persistence  of  uncontrolled  HT  after  monitoring  for  15
days;
good  compliance  with  treatments  evaluated  at  the
patient  interview;
glomerular  ﬁltration  rate  more  than  45  mL/min/1.73  m2.The  anatomy  of  the  renal  arteries  was  to  be  compatible
ith  the  endovascular  denervation  technique:
a  main  renal  artery  on  each  side  of  at  least  20  mm  in  length
and  4  mm  in  diameter;
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Table  1  Effects  of  renal  denervation  on  blood  pressure  in  SIMPLICITY  1  and  2.
Inclusion  Change  in
BP  at  1
month
Change  in
BP  at  3
months
Change  in
BP  at  6
months
Change  in
BP  at  9
months
Change  in
BP  at  12
months
Change  in
BP  at  24
months
Pilot  study  (SIMPLICITY  1)
Consultation  BP  177/101
(n  =  45)
—14/—10
(n =  41)
—21/—10
(n =  39)
—22/—11
(n =  26)
—24/—11
(n =  20)
—27/—17
(n =  9)
ND
ABPM  (n  =  12)
Mean  of  SBP  over  24  hours
ND  ND  ND  ND  ND  —11  mm  Hg
(95%  CI:  7)
(n  =  9)
ND
Randomised  study  (SIMPLICITY  2)
Consultation  blood  pressure
in  the  denervation  group
(n =  52)
178/97  —20/—6
(versus
control,
n  =  46)
—33/—11
(versus
control,
n  =  46)
ND
Automatic  measurement  —22/—12
(versus
control,
n  =  32)
ND
AMBP  over  24  h  —8/—6
(versus
control,
n  =  20)
ND
Follow-up  of  the
cohort  at  24
months  (n  =  18,
patients  in
SIMPLICITY  1
and  other
similar
patients)
•
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•
•
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t• absence  of  renal  artery  stenosis  or  history  of  revasculari-
sation  procedures;
• denervation  could  not  be  carried  out  due  to  anatomical
abnormalities  in  10  to  20%  of  pre-selected  patients  in  the
SIMPLICITY  studies.
Effects of renal denervation on blood pressure
The  effects  on  BP  were  evaluated  at  6  months  following
renal  denervation  [12—14]  (Table  1):
• in  86  patients  of  a  group  of  153  patients  treated
on  an  open-label  basis,  the  decrease  in  systolic  BP
(SBP)/diastolic  BP  (DBP)  was  of  25/11  mmHG,  respec-
tively,  clinically  measured;
• in  49  patients  treated  with  renal  denervation  in  SIM-
PLICITY  2,  the  decrease  in  SBP/DBP  was  of  32/12  mmHg,
respectively,  clinically  measured.  By  comparison,  in  51
patients  in  the  control  group  treated  with  medicinal
products,  the  decrease  in  SBP/DBP  was  of  1/0  mmHg,
respectively;• the  percentage  of  patients  treated  with  renal  denervation
with  a  SBP  less  than  140  mmHg  was  39%;
• the  percentage  of  responding  patients  (decrease  in  SBP
more  than  or  equal  to  10  mmHg)  was  85%  in  patients
A
o
atreated  with  renal  denervation  and  35%  in  the  group
treated  with  medicinal  products;
in  the  20  patients  treated  with  renal  denervation  in  SIM-
PLICITY  2,  an  evaluation  of  BP  by  ABPM  was  performed
before  and  after  6  months  of  follow-up.  The  decrease  in
SBP/DBP  was  of  11/7  mmHg,  respectively,  in  the  dener-
vated  group;
10%  of  patients  had  no  BP  beneﬁt  from  renal
denervation;
the  decrease  in  BP  was  not  immediate  after  the  proce-
dure.  The  maximum  effect  was  observed  after  3  months
of  follow-up;
antihypertensive  treatments  were  not  decreased  in  most
subjects  and  total  treatment  discontinuation  was  not  car-
ried  out  in  any  patients;
renal  denervation  was  not  accompanied  by  orthostatic
hypotension.
ffects of renal denervation on the activity of
he sympathetic nervous system reduction  in  renal  and  overall  sympathetic  activity  was
bserved  in  ten  subjects  in  the  SIMPLICITY  2  study,  30  days
fter  renal  denervation.
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omplications observed from renal
enervation  applied via the endovascular
oute
uring  the  renal  denervation  procedure,  intense  pain  is  felt
y  the  patient  and  the  application  of  the  technique  requires
uitable  analgesia  carried  out  by  an  anaesthetist.  In  the
IMPLICITY  2  study,  in  seven  patients  out  of  52,  it  was  nec-
ssary  to  use  atropine  during  the  procedure  due  to  the
nset  of  bradycardia.  In  the  SIMPLICITY  1  study,  of  the  45
atients  followed-up,  one  case  of  renal  artery  dissection  was
bserved  as  well  as  one  case  of  pseudo-aneurism  to  the  point
f  femoral  puncture.
In  the  SIMPLICITY  2  study,  of  the  52  patients  who  had  the
nitial  procedure,  the  following  were  observed:  one  case  of
emoral  pseudo-aneurism,  one  case  of  hypotension  requir-
ng  a  reduction  in  the  number  of  antihypertensive  agents
rescribed,  one  case  of  urinary  tract  infection,  once  case  of
ost-procedure  paresthesia  and  one  case  of  lumbago  that
esolved  after  one  month.  During  the  24-month  monitor-
ng  period  of  a  cohort  including  153  patients  treated  on
n  open-label  basis  [14], one  renal  artery  dissection  and
hree  femoral  pseudo-aneurisms  were  observed.  Follow-up
t  6  months  of  the  anatomy  of  the  renal  arteries  (mainly  by
oppler)  in  43  evaluable  patients  treated  in  the  randomised
tudy  and  81  patients  treated  on  an  open-label  basis  showed
o  vascular  abnormalities  in  the  treated  areas.  One  case
f  renal  artery  stenosis  that  progressed  after  6  months  of
ollow-up  and  that  required  angioplasty  was  reported.  Kid-
ey  function  in  49  patients  in  the  SIMPLICITY  2  study  with
n  initial  GFR  more  than  45  mL/min  remained  stable  at  6
onths  following  denervation.  No  longer-term  data  is  avail-
ble.
Two  patients  from  the  cohort  monitored  for  24  months
ied  (one  myocardial  infarction  and  one  sudden  death)  dur-
ng  the  follow-up  period.  These  deaths  were  not  attributed
o  the  denervation  procedure.  In  all,  3.5%  of  patients
ncluded  in  these  studies  had  an  early  adverse  event.  The
ow  number  of  patients  included  in  these  studies  does  not
urrently  make  it  possible  to  rule  out  a  rare  and  serious
isk  with  a  frequency  of  less  than  5%  in  the  short,  medium
nd  long-term  and  currently  justiﬁes  indeﬁnite  clinical  and
adiology  monitoring  of  patients  who  have  had  renal  arterial
enervation.
xperience with renal denervation in the
reatment of hypertension is still limited
he  limits  concerning  the  results  of  published  studies  are  as
ollows:
the  numbers  of  patients  included  in  the  studies  are  very
low  (202  patients  whose  results  were  published);
the  duration  of  follow-up  is  short,  which  does  not  make
it  possible  to  evaluate  the  risk  of  rare  and/or  long-term
adverse  effects;
the  patients  included  did  not  all  beneﬁt  from  optimal  anti-
hypertensive  treatment,  as  5  to  10%  did  not  receive  a
diuretic  and  less  than  20%  received  an  anti-aldosterone
agent;A.  Pathak  et  al.
the patients  included  in  the  studies  did  not  all  beneﬁt
from  APBM/AMBP,  which  is  the  way  to  screen  for  uncon-
trolled  HT  caused  by  the  white-coat  effect;
the  results  on  BP  beyond  24  months  are  not  known;
the  study  of  the  activation  of  the  sympathetic  system,
which  is  based  on  the  use  of  complex  experimental  tech-
niques,  cannot  be  performed  in  clinical  practice;
no  criteria  make  it  possible  to  predict  the  intensity  of
the  decrease  in  BP  induced  by  renal  denervation  via  the
endovascular  route;
no  markers  are  currently  available  to  indicate  an  effect
on  the  renal  sympathetic  system  during  and  after  the  pro-
cedure.
The  analysis  of  the  data  in  the  literature  indicate  that
ew  studies  need  to  be  conducted  in  order  to  answer  the
uestions  that  have  yet  to  be  resolved  concerning  renal
enervation  for  the  treatment  of  HT:
quantiﬁcation  of  the  decrease  in  BP  using  ABPM/AMBP;
criteria  predictive  of  the  efﬁcacy  of  renal  denervation  via
the  endovascular  route  on  BP;
criteria  of  the  efﬁcacy  of  renal  denervation  during  the
procedure;
BP  efﬁcacy  and  anatomical  change  in  renal  arteries  after
long-term  follow-up;
medico-economic  evaluation  of  renal  denervation  via  the
endovascular  route  as  a  method  of  treatment  for  resistant
HT.
Indications  of  renal  denervation  via  the  endovascular
route  in  the  treatment  of  hypertension  in  2012
In  2012,  the  expert  consensus  limits  the  indication  of
the  technique  of  renal  denervation  to  patients  who
have  essential  uncontrolled  HT  receiving  four  or  more
treatments  (Appendix  A):
• with  a  treatment  including  at  least  one  diuretic;
• spironolactone  at  a  dose  of  25  mg  that  has  been
ineffective;
• with  at  least  SBP  more  than  160  mmHg  and/or  DBP
more  than  100  mmHg  in  consultation;
• and  conﬁrmation  of  SBP  more  than  135  mmHg  and
DBP  more  than  85  mmHg  via  ABPM  or  by  AMBP
(daytime  period);
• with  a  glomerular  ﬁltration  rate  more  than
45  mL/min/1.73  m2;
• with  renal  artery  anatomy  that  is  compatible  with
the  procedure;
• with  the  presence  of  two  functioning  kidneys
measuring  more  than  or  equal  to  90  mm;
• who  have  had,  before  the  procedure,  an
exploration  of  the  renal  arteries  via  a  radiology
imaging  technique  (angio-CT  scan,  angio-MRI  or
arteriography);
• with  no  history  of  angioplasty/stent  in  the  target
renal  arteries;
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• with  an  approach  route  compatible  with  the
procedure;
• with  an  indication  established  after  multi-
disciplinary  discussion  including  a  physician  who  has
practice  and  skill  in  the  treatment  of  patients  with
HT.
The  renal  denervation  technique  cannot  be  used  in
patients  with  HT  and:
• renal  artery  stenosis  more  than  30%;
• renal  artery  ﬁbro-muscular  dysplasia;
• who  are  under  18  years  of  age;
•
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The  recommendations  for  the  follow-up  of  patients  whowho  are  currently  pregnant.
Recommended procedure for renal
denervation via the endovascular route in
the  treatment of hypertension
The  expert  consensus  brought  together  in  2011  recom-
mended  the  following  organisation  and  procedure  for  the
application  of  renal  denervation  technique  via  the  endovas-
cular  route.
Technical facilities
Suitable  technical  facilities  should  include  an  angiography
room  that  allows  for  the  following:
• a  good  visualisation  of  the  two  nephrogrammes  in  overall
angiography;
• high  quality  scopy.  Use  of  an  OR-mobile  C-arm  is  not  suit-
able  for  this  procedure;
• optimal  radioprotection  conditions.
• The  images  should  include:
• imaging  of  the  kidneys,  right  and  left  renal  arteries
before  and  after  the  renal  denervation  (overall  aortog-
raphy  with  delayed  sequences  that  ensure  the  absence  of
renal  embolic  complications  or  dissection);
• images  from  the  beginning  and  the  end  of  the  procedure
as  well  as  the  position  of  the  catheter  at  the  different
removal  sites  must  be  archived  in  a  computer  system.
The  angiography  room  must  be  located  in  an  environ-
ment  that  makes  it  possible  for  an  anaesthetist  to  perform
sedation/analgesia.
Operator training
Renal  denervation  is  a  complex  procedure  that  can  have  risks
of  arterial  complications.  Training  is  necessary  for  the  ﬁrst
cases  as  well  as  learning  how  to  use  the  speciﬁc  material.
Interventional  radiologists/cardiologists  should  have  carried
out  either:
• 15 renal  arterial  angioplasties  ±  stent;
• or  ten  renal  arterial  angioplasties  and  50  peripheral  arte-
rial  angioplasties  within  the  last  2  years;
• or  have  carried  out  renal  angioplasties  on  a  regular  basisin  the  past  5  years  (5/year)  and  regularly  performed  renal
arterial  catheterisation  for  embolisation  regardless  of  the
cause  on  a  regular  basis  (10/year  in  the  last  2  years).ension  391
rocedure for renal denervation by
adiofrequency
he  procedure  requires  the  insertion  via  the  renal
ntra-arterial  route,  as  per  the  principles  of  arterial
atheterisation,  of  a  speciﬁc  single-use  catheter  that  allows
or  renal  denervation.  The  denervation  catheter  approved
or  the  treatment  of  the  renal  arteries  is  coupled  with  a
enerator  of  low-energy  radiofrequency  current,  the  ther-
al  effect  of  which  dissipates  in  the  adventitia  of  the  renal
rtery  in  which  the  afferent  and  efferent  sympathetic  nerve
bres  are  located  and  destroys  them.
The  method  should  follow  a  standardised  procedure:
orrect  positioning  conﬁrmed  by  impedancemetry,  deliv-
ry  of  radiofrequency  current,  cooling  of  the  extremity  of
he  catheter  by  blood  ﬂow,  impulse  sequence  for  a  dura-
ion  of  2  minutes,  the  power  delivered  by  the  catheter
nd  the  temperature  collected  in  real  time  that  conditions
ater  impulses,  withdrawal  with  a  60◦ to  90◦ rotation  of  the
atheter  per  5  mm  interval  starting  from  the  initial  removal
one  close  to  the  renal  hilum,  the  performance  of  four  to
ix  deliveries  of  radiofrequency  current,  circumferential  and
ocal  denervation  following  a  helicoidal  pattern.  The  renal
enervation  procedure  can  be  performed:
if  there  is  at  least  one  renal  artery  on  each  side,  the
diameter  of  which  is  greater  than  4  mm;
if  the  length  of  the  main  trunk  of  the  renal  artery  is  at
least  20  mm,  making  it  possible  to  deliver  at  least  four
shots;
in  one  artery  only  of  each  kidney.
During  the  procedure,  the  following  minimal  actions
hould  be  undertaken:
monitoring  of  vital  signs  (heart  rate,  BP,  etc.);
anti-coagulation  with  heparin  at  an  effective  dose;
nitrate  derivatives  by  injection  in  the  renal  artery  before
the  procedure;
checking  the  programming  of  a  cardiac  stimulator  or  an
automatic  deﬁbrillator  after  the  procedure  if  renal  dener-
vation  is  performed  in  a  patient  with  this  type  of  device.
In  case  of  vascular  complications  during  the  procedure,
t  is  necessary  to:
have  speciﬁc  material  available  in  the  catheterisa-
tion/angiography  room  that  makes  it  possible  to  urgently
implant  a  stent  of  a  suitable  calibre  (6  mm)  in  the  renal
artery  in  case  of  dissection;
interrupt  the  procedure  in  case  of  a  vascular  complication
occurring  in  one  of  the  arteries;
report  the  complication  to  the  materiovigilance  centre  of
the  site.
Follow-up  of  patients  who  have  had  renal
denervation  via  the  endovascular  route  for  the
treatment  of  hypertensionhave  had  renal  denervation  are:
392  
• In the  short-term,  the  patient  should  be  monitored
as  per  the  monitoring  rules  of  a  renal/peripheral
arterial  angioplasty.  Monitoring  for  1  hour  is  desirable
in  the  post-procedure  monitoring  room  before
returning  to  the  hospital  room  and  a  hospital  stay
of  24  h.
• Monitoring  of  BP  (ABPM/AMBP):  after  6  months,  after
12  months,  after  24  months,  after  36  of  the  renal
denervation  procedure.
• Monitoring  of  the  anatomy  of  the  renal  arteries:
angio-CT  scan  (optimal  analysis  of  the  anatomy  of  the
renal  arteries)  after  12  months  and  after  36  months
of  the  renal  denervation  procedure.
• Usual  monitoring  of  kidney  function  within  the
framework  of  HT,  including  the  following  in
particular:  serum  creatinine  levels,  proteinuria  (if
initial  proteinuria)  after  6  months,  after  12  months,
after  24  months,  after  36  months  of  the  renal
denervation  procedure.
• The  antihypertensive  treatment  should  not  be
interrupted  immediately  after  the  renal  denervation
procedure,  as  the  effect  on  the  decrease  in  BP  is
delayed  and  reaches  its  maximum  effect  after  3
months  according  to  the  SIMPLICITY  studies.
• Changes  in  the  antihypertensive  treatment  should
be  carried  out  by  the  physician  treating  the  patient
for  HT.  The  expert  consensus  mandates  the  inclusion
in  the  SFHTA/SFC/SFR/GACI  register  for  ‘‘renal
denervation  in  HT’’  of  all  patients  in  France  who
have  had  the  renal  denervation  technique,  either
within  the  framework  of  a  studies  and/or  protocols
or  within  the  framework  of  clinical  treatment  outside
of  a  protocol.
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ppendix A. Information leaﬂet for
atients having renal denervation via the
ndovascular route with radiofrequency
enal denervation via the endovascular route
or the treatment of hypertensionour  BP  remains  too  high  despite  the  use  of  several  antihy-
ertensive  medicines.  We  are  offering  you  a  new  technique
e
m
iA.  Pathak  et  al.
alled  renal  denervation  that  can  improve  the  efﬁcacy  of
he  HT  treatments.
ow does it work?
he  principle  of  renal  denervation  is  to  interrupt  the  activ-
ty  of  the  sympathetic  nerves  that  surround  the  arteries  of
he  kidneys  and  that  participate  in  HT.  The  method  uses
eat  emitted  by  a  miniature  device  positioned  at  the  end
f  a  catheter  that  is  inserted  in  the  arteries  that  lead  to
he  kidneys  (renal  arteries).  The  heat  is  generated  by  a
ystem  using  a  radiofrequency  current  specially  developed
n  a  medical  device  with  a  technical  evaluation  (CE  label)
aking  it  possible  to  use  it  in  the  European  Union  and  in
rance.
At  the  beginning  of  the  year  2012,  this  system  had  been
sed  in  a  few  hundred  patients  in  the  world.  The  results
f  clinical  studies  concluded  that  renal  denervation  can  be
sed  to  reduce  BP  in  patients  with  uncontrolled  HT  despite
edicinal  treatment,  and  that  the  risks  related  to  this
ethod  are  minimal.
hat happens during the procedure?
he  procedure  will  be  performed  in  a  department  that
akes  it  possible  to  carry  out  interventional  radiology  exam-
nations.  To  avoid  pain  associated  with  this  procedure,  you
ill  be  given  medicines  that  will  make  you  sleepy  and
ill  relax  you.  In  some  cases,  general  anaesthesia  may  be
iven.
The  procedure  will  begin  with  arteriography  that  will
isualise  the  renal  arteries.  After  local  anaesthesia,  a  needle
ill  be  inserted  into  the  groin  making  it  possible  to  introduce
 tube  (catheter)  with  a  small  diameter  (about  1.7  mm)  into
he  femoral  artery.  The  catheter  will  then  be  inserted  into
he  main  renal  arteries  under  radiological  monitoring  and  it
ill  be  injected  with  a  contrast  medium  that  will  make  it
ossible  to  see  the  renal  arteries.
Once  the  renal  arteries  have  been  located,  the  speciﬁc
atheter  that  carries  the  radiofrequency  system  will  be  posi-
ioned  in  the  renal  artery.  The  treatment  will  be  applied
ia  2  minutes  sequence  for  four  to  six  sequences  in  each
enal  artery.  After  having  treated  each  renal  artery  (left  and
ight),  the  material  will  be  withdrawn.
At  the  end  of  the  examination,  prolonged  compression  of
he  groin  will  be  performed  to  avoid  bruising  at  the  punc-
ure  point.  A  compressive  bandage  will  be  applied.  You  will
hen  have  to  remain  lying  down  for  24  hours  under  medical
onitoring.  You  will  be  allowed  to  get  up  from  your  bed  and
alk  starting  from  the  24th  hour  after  the  procedure.  You
ill  then  be  able  to  go  home.
ollow-up visits
ou  will  be  seen  again  regularly  in  consultation  for  moni-
oring  visits  at  3,  6  12  and  24  months  after  the  procedure
o  monitor  your  BP  and  to  adjust  the  number  of  your  anti-xamination  of  the  renal  arteries  be  carried  out  after  12
onths  and  after  36  months  to  monitor  the  proper  function-
ng  of  the  renal  arteries.
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What is the expected beneﬁt?
The  expected  beneﬁt  of  the  renal  denervation  technique
is  an  improvement  in  the  efﬁcacy  of  HT  treatments  on  BP.
Before  the  procedure,  it  is  not  possible  to  predict  the  extent
of  the  decrease  in  BP  that  will  be  obtained  through  renal
denervation.  According  to  the  published  studies,  in  most
patients  treated  with  renal  denervation,  a  decrease  in  BP  is
observed  that  is  at  its  maximum  3  months  after  the  proce-
dure.  This  decrease  in  BP  makes  it  possible  to  decrease  the
number  of  medicines  necessary  to  treat  your  HT.  However,
it  is  rarely  possible  to  discontinue  all  the  medicines.
What are the risks?
The  main  risks  related  to  the  renal  denervation  procedure
are  similar  to  those  run  during  any  diagnostic  or  therapeu-
tic  investigation  (for  example,  during  dilation  of  an  artery
with  or  without  the  insertion  of  an  endoprosthetic)  involving
arterial  catheterization.  With  regard  to  safety,  two  studies
have  investigated  the  short  and  medium-term  risk  of  the
technique  (6  to  12  months).  The  safety  data  published  to
date  concern  the  202  patients  who  have  been  treated  with
the  procedure.
The  frequency  of  the  onset  of  complications  remains  very
low,  particularly  for  the  most  serious  complications  (one
reported  case  of  dissection  of  a  renal  artery  treated  with
a  stent).  Pain  and  bruising  at  the  arterial  puncture  point  in
the  groin  are  the  local  complications  for  which  the  frequency
is  highest  (1  to  10%).  These  data  are  reassuring.  Check-
ing  the  condition  of  the  renal  arteries  a  certain  period  of
time  afterwards  (6  to  12  months)  showed  no  kidney  function
abnormalities  (kidney  function  stable).  List  of  complications
that  may  occur  during  renal  denervation  via  the  endovascu-
lar  route:
General  complications  related  to  arteriography:
frequency  of  less  than  1%:
• Nausea  or  vomiting
• Complications  related  to  the  use  of  contrast  media  such
as  allergic  reactions  or  renal  insufﬁciency  related  to  the
contrast  medium.
• Heart  rhythm  disturbances,  for  example,  heart  rate  that
is  too  slow
• HT -  BP  that  is  too  low
• HT  -  BP  that  is  too  high
• Intra-peritoneal  bleeding  -  (bleeding  in  the  intra-
abdominal  area)
• Fever  after  the  procedure  that  may  or  may  not  be  related
to  an  infection
• Death
Local  complications  related  to  arteriography:
frequency  of  less  than  1%:
• Arterial  embolism  (clot  that  can  temporarily  or  perma-
nently  affect  the  functioning  of  some  organs).
• Vascular  complications  (requiring  surgery).
• Perforation  or  dissection  of  a  renal  artery  (requiring  the
insertion  of  an  arterial  stent).
• Pain  at  the  puncture  site.
• Bruise,  pseudo-aneurism  (dilation  of  the  arterial  wall).ension  393
Arterio-venous  ﬁstula  (abnormal  communication  between
a  vein  and  an  artery).
Local  infection.
External  bleeding  (at  the  puncture  site).
omplications  related  to  the  renal  denervation:
requency  of  less  than  1%:
Abdominal  pain  during  the  procedure  that  is  attenuated
or  avoided  by  the  use  of  analgesics  and/or  anaesthet-
ics.  These  medicines  can  themselves  decrease  BP  and/or
breathing  rate,  and  sometimes  results  in  nauseous  sensa-
tions  or  even  vomiting  and  constipation.
Damage  to  the  arterial  wall  related  to  radiofrequencies
and/or  ultrasounds  (theoretical  risk).
Hypotension,  particularly  when  standing  (but  the
observed  drop  in  BP  occurs  gradually  over  a  period  of
weeks).
Haematuria  (blood  in  the  urine).
Other  risks  that  are  not  currently  known  (like  with  any
new  treatment).
Like any  new  procedure,  other  risks  that  are  not  currently
known  cannot  be  ruled  out.  Their  incidence  is  very  low.
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